Mean cardiopulmonary dose and vertebral marrow dose differentially predict lineage-specific leukopenia kinetics during radiotherapy for esophageal cancer
Esophageal cancer (EC) carries a poor prognosis with median five-year survival rate of 15% –25% [1]. It is the eighth most common cancer diagnosed worldwide, with incidence increasing [1–3]. Locally advanced esophageal carcinoma (cT1-4N1M0/T4N0M0) is optimally treated with multimodality therapy including chemotherapy, radiotherapy, and surgery [4,5]. In surgical candidates, evidence s uggests that trimodality therapy including neoadjuvant CRT followed by esophagectomy improves overall survival [5–9].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Joshua L. Anderson, Neil B. Newman, Chelsea Anderson, Alexander D. Sherry, Adam D. Yock, Evan C. Osmundson Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Cardiology | Chemotherapy | Esophagectomy | Esophagus Cancer | Heart | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Radiology